Navigation Links
Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA)
Date:9/17/2007

tcomes of such studies, Pharmacopeia's estimates of the market opportunities for its product candidates, including PS433540, Pharmacopeia's ability to successfully perform under its collaborations with Cephalon, GlaxoSmithKline, Organon and Wyeth, Pharmacopeia's ability to build its pipeline of novel drug candidates through its own internally-funded drug discovery programs, third party collaborations and in-licensing, Pharmacopeia's ability to raise additional capital, Pharmacopeia's expectations concerning the development priorities of its collaborators, their ability to successfully develop compounds and its receipt of milestones and royalties from the collaborations, Pharmacopeia's anticipated operating results, financial condition, liquidity and capital resources, Pharmacopeia's expectations concerning the legal protections afforded by U.S. and international patent law, Pharmacopeia's ability to pursue the development of new compounds and other business matters without infringing the patent rights of others, additional competition, and changes in economic conditions.

Further information about these and other relevant risks and uncertainties may be found in Pharmacopeia's Reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Pharmacopeia urges you to carefully review and consider the disclosures found in its filings which are available in the SEC EDGAR database at http://www.sec.gov and from Pharmacopeia at http://www.pharmacopeia.com. All forward-looking statements in this press release and oral statements made with respect to information contained in this press release are qualified entirely by the cautionary statements included in this press release and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by such forward-looking statements. Thes
'/>"/>

SOURCE Pharmacopeia
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacopeia Announces Positive Results from Initial DARA Clinical Trial
2. Malvern initiates European user group meetings for chemical imaging
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... July 31, 2015 According to a ... (Moist Heat, Dry Heat, Ethylene Oxide, Filtration, E-beam, Gamma), Services ... (Hospitals, Pharmaceuticals) - Global Forecast to 2020", published by MarketsandMarkets, ... 6.1 Billion by 2020, at a CAGR of 7.6%.from 2015 ... market data T ables and 37 ...
(Date:7/31/2015)... and SAN DIEGO , July 31, ... company Eisai Co., Ltd. (Headquarters: Tokyo ... and Halozyme Therapeutics, Inc. (Headquarters: San Diego, ... Torley , "NASDAQ: HALO") have signed a clinical collaboration ... ® , "eribulin") in combination with Halozyme,s investigational drug ...
(Date:7/30/2015)... Mettler-Toledo International Inc. (NYSE: MTD ) today announced ... highlights: , Sales in local currency increased ... Reported sales decreased 4% as currency reduced sales growth ... per diluted share as reported (EPS) were $2.73, compared ... $2.80 , an increase of 9% over the ...
Breaking Medicine Technology:Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 2Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 3Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14
... , Feb. 4 Accuray Incorporated (Nasdaq: ARAY ), ... for the second quarter of fiscal year 2010, ended December 31, ... reported total revenue of $57.3 million , compared to the second ... , Accuray reported a net loss for the second quarter of fiscal ...
... , , ATLANTA , Feb. ... for Economic and Clinical Health (HITECH) Act, Elekta has expanded its ... advantage of the financial incentives available from the federal government. These ... certified EMR systems who are able to demonstrate meaningful use. , ...
Cached Medicine Technology:Accuray Announces Results for Second Quarter Fiscal 2010 2Accuray Announces Results for Second Quarter Fiscal 2010 3Accuray Announces Results for Second Quarter Fiscal 2010 4Accuray Announces Results for Second Quarter Fiscal 2010 5Accuray Announces Results for Second Quarter Fiscal 2010 6Accuray Announces Results for Second Quarter Fiscal 2010 7Accuray Announces Results for Second Quarter Fiscal 2010 8Accuray Announces Results for Second Quarter Fiscal 2010 9Accuray Announces Results for Second Quarter Fiscal 2010 10Accuray Announces Results for Second Quarter Fiscal 2010 11Accuray Announces Results for Second Quarter Fiscal 2010 12Elekta Expands Consultative Services Program to Help MOSAIQ Customers Demonstrate Meaningful Use Guidelines 2Elekta Expands Consultative Services Program to Help MOSAIQ Customers Demonstrate Meaningful Use Guidelines 3
(Date:8/1/2015)... Humble, TX (PRWEB) , ... August 01, 2015 , ... ... common concern among both men and women often causing pain and discomfort. Those who ... to this circulatory problem, and Northeast Houston Vein Center is doing what it can ...
(Date:8/1/2015)... New York, NY (PRWEB) , ... August 01, 2015 , ... ... Black Vine cyberespionage group , who are thought to have been behind the attack ... Among the topics covered were zero day exploits, watering hole attacks and spear phishing ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... High Times magazine. What are the STASH awards? The Significant Technological Achievements ... by the cannabis-cultivation community as well as tried-and-true products that have stood the ...
(Date:7/31/2015)... Chicago, IL (PRWEB) , ... July 31, 2015 , ... ... which is currently going on in Chicago at Grant Park. The festival ... every corner of North America to Chicago for the annual Lollapalooza. This unique ...
(Date:7/31/2015)... ... 31, 2015 , ... Sculpted Contours Luxury Medical Aesthetics announces the arrival of ... Aesthetics released this new applicator in the United States as an upgrade to the ... The original applicator required a 2 hour treatment time. The new CoolSmooth ...
Breaking Medicine News(10 mins):Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 2Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 4Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3
... August 18, 2008Young researchers presented innovative, early-stage research ... collaborative project of the AUA Foundation and the ... 7-9, 2008. The AUA Foundation hosted the forum ... most cutting-edge research in sexual medicine. These ...
... 19 On September 18,Seabrook House, a nationally ... quarterly ,Inside MatriArk Family Center, open house,from 10:00 ... invited to check out,the 42,000-square-foot center and learn ... offer., This exciting event gives outsiders an ...
... Series A Funding of Healthcare Startup, NEW ... helps,consumers find and book doctor appointments online, today ... round of financing led by Khosla Ventures.,ZocDoc is ... (Logo: http://www.newscom.com/cgi-bin/prnh/20080819/LATU010LOGO ), ZocDoc uses ...
... ... Practitioners, NEWPORT BEACH, Calif., Aug. ... Managed Compliance Services,Program (MCSP) for small healthcare practitioners -- the first ... is tailored to meet the HIPAA compliance,requirements of small healthcare practitioners. ...
... - Clinical evidence for unique Ranexa(R) mechanism of action ... Therapeutics,Inc. (Nasdaq: CVTX ) announced today that the ... showing that,ranolazine significantly (p<0.001) shortened the QT interval of ... LQT3. Ranolazine also,shortened cardiac relaxation time in the study., ...
... Search, RARITAN, N.J., Aug. 19 The first ... identify real-life "It Girls" who embody,confidence and reliability was ... Millennial generation, the finalists proved that intelligence,reliability, talent and ... this much talked about group. The "It Girl Essentials" ...
Cached Medicine News:Health News:New research on sexual function 2Health News:Seabrook House Welcomes Visitors to MatriArk Family Center 2Health News:Khosla Ventures Into Healthcare With ZocDoc 2Health News:Managed Compliance Services Program (MCSP) Introduced for Small Healthcare Practitioners 2Health News:Managed Compliance Services Program (MCSP) Introduced for Small Healthcare Practitioners 3Health News:Journal of Cardiovascular Electrophysiology Publishes Data Showing Ranolazine Shortened QT Interval and Improved Cardiac Relaxation in Study of Patients With Long QT Syndrome 2Health News:Journal of Cardiovascular Electrophysiology Publishes Data Showing Ranolazine Shortened QT Interval and Improved Cardiac Relaxation in Study of Patients With Long QT Syndrome 3Health News:Reliability & Confidence Define a Nation Of 'It Girls' 2Health News:Reliability & Confidence Define a Nation Of 'It Girls' 3Health News:Reliability & Confidence Define a Nation Of 'It Girls' 4Health News:Reliability & Confidence Define a Nation Of 'It Girls' 5
Provides outstanding patient warming and safety throughout the hospital and is nearly half the size and one-third the weight of earlier units....
The SnuggleWarm Convective Warming provides the technology and the tools to effectively enhance the quality of patient care....
The product, which is comprised of a non-intrusive panty-liner, offers a simple to use classification tool that uses color identification for interpretation of the results....
The Affirm™ VPIII tests RNA probe technology offers a dependable, rapid means toward early identification and treatment of patients suffering from these pathogens....
Medicine Products: